SuperworthClene EPS CLNN
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Sep 30, 2022
- −$7.60
- Latest quarter, Q3 FY22
- −$3.40
- −140% on a year earlier
- Fiscal year 2021
- −$4.40
Clene's earnings per share was −$7.60 over the twelve months to Sep 30, 2022.
In its latest quarter, Q3 FY22, it was −$3.40, down 140% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2021 | −$4.40 | n/a |
| FY2020 | −$22.40 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY22 | −$3.40 | −140% | −$7.60 | |
| Q2 FY22 | −$1.40 | n/a | $4.20 | |
| Q1 FY22 | −$4.20 | n/a | $4.60 | |
| Q4 FY21 | $1.40 | +75% | −$4.40 | |
| Q3 FY21 | $8.40 | n/a | −$5.00 | |
| Q2 FY21 | −$1.00 | n/a | −$25.20 | |
| Q1 FY21 | −$13.20 | n/a | −$31.00 | |
| Q4 FY20 | $0.80 | n/a | −$22.40 | |
| Q3 FY20 | −$11.80 | n/a | n/a | |
| Q2 FY20 | −$6.80 | n/a | n/a | |
| Q1 FY20 | −$4.60 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Clene's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CLNNClene | n/m | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Clene
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.